A detailed history of Citigroup Inc transactions in Xencor Inc stock. As of the latest transaction made, Citigroup Inc holds 80,059 shares of XNCR stock, worth $2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80,059
Previous 52,718 51.86%
Holding current value
$2 Million
Previous $997,000 61.38%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$15.7 - $21.65 $429,253 - $591,932
27,341 Added 51.86%
80,059 $1.61 Million
Q2 2024

Aug 12, 2024

SELL
$18.21 - $24.5 $3.21 Million - $4.32 Million
-176,393 Reduced 76.99%
52,718 $997,000
Q1 2024

May 10, 2024

BUY
$18.65 - $26.52 $2.74 Million - $3.9 Million
146,954 Added 178.87%
229,111 $5.07 Million
Q4 2023

Feb 09, 2024

BUY
$16.53 - $21.42 $196,178 - $254,212
11,868 Added 16.88%
82,157 $1.74 Million
Q3 2023

Nov 09, 2023

SELL
$20.08 - $25.39 $142,106 - $179,685
-7,077 Reduced 9.15%
70,289 $1.42 Million
Q2 2023

Aug 10, 2023

SELL
$24.77 - $29.9 $1.32 Million - $1.6 Million
-53,400 Reduced 40.84%
77,366 $1.93 Million
Q1 2023

May 11, 2023

BUY
$25.95 - $36.95 $1.04 Million - $1.48 Million
40,080 Added 44.2%
130,766 $3.65 Million
Q4 2022

Feb 09, 2023

SELL
$24.79 - $30.86 $1.08 Million - $1.35 Million
-43,617 Reduced 32.48%
90,686 $2.36 Million
Q3 2022

Nov 10, 2022

BUY
$24.62 - $32.44 $900,279 - $1.19 Million
36,567 Added 37.41%
134,303 $3.49 Million
Q2 2022

Aug 10, 2022

BUY
$19.74 - $29.01 $601,556 - $884,050
30,474 Added 45.31%
97,736 $2.67 Million
Q1 2022

May 12, 2022

SELL
$26.68 - $41.63 $790,955 - $1.23 Million
-29,646 Reduced 30.59%
67,262 $1.8 Million
Q4 2021

Feb 10, 2022

BUY
$33.67 - $43.44 $1.01 Million - $1.3 Million
29,896 Added 44.61%
96,908 $3.89 Million
Q3 2021

Nov 10, 2021

BUY
$30.65 - $35.68 $2.05 Million - $2.39 Million
67,012 New
67,012 $2.19 Million

Others Institutions Holding XNCR

About Xencor Inc


  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.49B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.